Comparison of acute cholangitis with or without common bile duct dilatation

MINORU TOMIZAWA¹, FUMINOBU SHINOZAKI², RUMIKO HASEGAWA³, YOSHINORI SHIRAI³, YASUFUMI MOTOYOSHI⁴, TAKAO SUGIYAMA⁵, SHIGENORI YAMAMOTO⁶ and NAOKI ISHIHE⁷

Departments of ¹Gastroenterology, ²Radiology, ³Surgery, ⁴Neurology, ⁵Rheumatology, ⁶Pediatrics and ⁷Neurosurgery, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan

Received October 15, 2015; Accepted February 17, 2017

DOI: 10.3892/etm.2017.4401

Abstract. To improve the management of patients with acute cholangitis, the present study compared laboratory test variables between acute cholangitis patients with or without common bile duct (CBD) dilatation [CBDdil(+) and CBDdil(-), respectively]. The medical records of patients diagnosed with acute cholangitis and subjected to endoscopic retrograde cholangiopancreatography between February 2008 and May 2015 were retrospectively analyzed. The present study consisted of 40 men (aged 69.4±8.8 years) and 37 women (aged 68.8±11.6 years). It was observed that CBDdil(-) patients were slightly younger than CBDdil(+) patients (P=0.0976), and levels of C-reactive protein (CRP) were significantly higher in CBDdil(-) patients than in CBDdil(+) patients (P=0.0392). In addition, logistic regression analysis indicated that CRP levels were associated with the presence of CBD dilatation (P=0.0392). These data indicate that patients with acute cholangitis without CBD dilatation tend to be younger and have higher levels of CRP. Thus, in acute cholangitis patients without CBD dilatation, diagnosis should be determined using clinical symptoms and laboratory data.

Introduction

Acute cholangitis is a bacterial inflammation that develops due to obstruction of the bile duct (1-3), typically by gallstones. A total of 76.6% of acute cholangitis cases are caused by gram-negative bacteria, including Escherichia coli and Klebsiella pneumoniae (4). Acute cholangitis may progress to sepsis, which in some cases is fatal, as the bacteria are able to translocate to the blood (5,6). In the clinical management of acute cholangitis, biliary drainage is generally performed (7) by endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography and endoscopic ultrasound-guided drainage (8). For prompt treatment of patients with acute cholangitis, accurate diagnosis is necessary.

Acute cholangitis is currently diagnosed based on evidence of bile duct obstruction and inflammation (9). Evidence of inflammation includes the presence of fever and elevations in white blood cell (WBC) count and C-reactive protein (CRP) levels, while bile duct obstruction is identified by elevated levels of liver enzymes, including total bilirubin (T-Bil), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (γ-GTP).

Diagnosis of acute cholangitis is typically confirmed by diagnostic imaging (9), including abdominal ultrasound (US), computed tomography (CT) and magnetic resonance cholangiopancreatography (MRCP). Abdominal US and CT are able to identify bile duct obstruction, dilatation of the common bile duct (CBD) and gallstones (10). For patients with contraindications to MRCP, the 3D structure of the CBD may be visualized with CT (11). However, these diagnostic imaging techniques primarily evaluate CBD dilatation, thus it is difficult to use imaging techniques to diagnose acute cholangitis in patients without CBD dilatation.

Therefore, the present study retrospectively compared the laboratory test variables and ages of acute cholangitis patients with or without CBD dilatation, with the aim of applying these results to improve patient management.

Patients and methods

Diagnosis and management of acute cholangitis. Patients at the National Hospital Organization Shimoshizu Hospital were diagnosed with acute cholangitis using the clinical Charcot’s triad criteria (Table I) (8) or the criteria for ‘suspected’ or ‘definite’ acute cholangitis according to the Tokyo guidelines (TG13) (9). Briefly, patients were diagnosed with acute cholangitis when they had the following Charcot’s triad: Fever, jaundice and abdominal pain. However, not all patients with acute cholangitis meet the Charcot’s triad criteria (12). Therefore, when patients did not meet the Charcot’s triad criteria but were suspected of having acute...
Table I. Diagnostic criteria for acute cholangitis based on Charcot's triad and the TG13.

<table>
<thead>
<tr>
<th>Charcot's triad</th>
<th>TG13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever, jaundice, abdominal pain</td>
<td>A. Systemic inflammation</td>
</tr>
<tr>
<td></td>
<td>- Fever and/or shaking chills, laboratory data, evidence of inflammatory response (WBC count and CRP levels)</td>
</tr>
<tr>
<td></td>
<td>B. Cholestasis</td>
</tr>
<tr>
<td></td>
<td>- Jaundice, laboratory data, abnormal liver function tests (ALP, AST, ALT and γ-GTP levels)</td>
</tr>
<tr>
<td></td>
<td>C. Imaging</td>
</tr>
<tr>
<td></td>
<td>- Biliary dilatation, evidence of disease etiology (including structure and stones)</td>
</tr>
</tbody>
</table>

Patients were diagnosed with acute cholangitis if they met the Charcot's triad criteria (8). If patients did not meet the Charcot's triad criteria, they were diagnosed with acute cholangitis if they met the criteria for suspected (one item in A + one item in either B or C) or definite (one item in each of A, B and C) acute cholangitis according to the TG13 (9). Imaging was performed with abdominal ultrasonography, computed tomography and magnetic resonance cholangiopancreatography. TG13, Tokyo guidelines 2013 edition; WBC, white blood cell; CRP, C-reactive protein; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase.

Inclusion and exclusion criteria. Patients were enrolled in the current study if they met the following inclusion criteria: i) Diagnosis with acute cholangitis according to the aforementioned criteria; ii) treatment with ERCP, and iii) hospitalization in the National Hospital Organization Shimoshizu Hospital between February 2008 and May 2015. Patients were excluded from the current study when they met the following exclusion criteria: i) Diagnosis with acute cholangitis but not subjected to ERCP, and ii) subjected to ERCP for reasons other than acute cholangitis. A total of 40 men (aged 69.4±8.8 years) and 37 women (aged 68.8±11.6 years) were enrolled in the current study. The cause of acute cholangitis in all but one patient was a CBD stone or sludge. The remaining patient had cancer of the CBD and a CBD stone. The current study was approved by the Ethics Committee of the National Hospital Organization Shimoshizu Hospital (Yotsukaido, Japan). Written informed consent was obtained from patients prior to abdominal US, CT with or without contrast enhancement. Informed consent was obtained from patients prior to ERCP, and CT with or without contrast enhancement. Informed consent was obtained from patients prior to abdominal US, though written informed consent was waived as abdominal US is considered to be safe and non-invasive. The current study was not considered a clinical trial as procedures were performed as part of routine clinical practice. Therefore, written informed consent for inclusion in the study was waived. All patient records were anonymized prior to retrospective analysis.

ERCP. Patients underwent moderate-level sedation with an intramuscular injection of 20 mg hydroxyzine (Pfizer, Inc., New York, NY, USA) and intravenous injection of 5 mg diazepam (Takeda, Osaka, Japan), and were under continuous cardiopulmonary monitoring. All ERCP procedures were performed by clinical endoscopists using an Evis Lucera duodenovideoscope JF-260V (Olympus Corporation, Tokyo, Japan). Cannulation of the bile duct was performed in all patients with a standard type cannula (PR-V216Q; Olympus Corporation). The cannula was used to detect CBD stones by fluoroscopy using a contrast medium (sodium meglumine diatrizoate; Bayer AG, Leverkusen, Germany). The cannula was then changed to a sphincterotome (KD-V411M-0720; Olympus Corporation) with a guidewire and endoscopic papillotomy (EPT) was performed. The CBD stones and/or sludge were removed with a balloon catheter (B-V232P-A; Olympus Corporation). For large or hard CBD stones, lithotripsy was initially performed with a lithotripter (BML-V437QR-30; Olympus Corporation), and the fractured CBD stones were removed with the lithotripter or balloon catheter. A nasobiliary catheter (NB-ST-CHBIN-72-3000-SH3-WP; Hanaco Medical Co., Ltd., Saitama, Japan) was inserted for drainage if necessary. Bile culture was not performed with ERCP. Following ERCP, patients were monitored for ERCP-related complications, including bleeding, perforation and/or pancreatitis. No such complications were observed.

Grouping of patients. The CBD diameter was measured using images from the ERCP procedure. Based on CBD measurements, enrolled patients were divided into the following two groups: A CBDdil(-) group for patients with a CBD diameter of ≤7.0 mm and a CBDdil(+) group for patients with a CBD diameter of >7.0 mm. Previous studies indicate that the upper...
limit of the CBD diameter in acute cholangitis ranges from 6.0 to 8.0 mm (14,15). In the current study, 7.0 mm was selected as the upper CBD diameter limit as this value is directly between 6.0 and 8.0 mm. The CBDdil(-) group was comprised of 10 men and 13 women and the CBDdil(+) group consisted of 30 men and 24 women (Table II). The gender ratio did not differ significantly between the two groups (P=0.3314).

Laboratory test variables. Laboratory test variables evaluated in the current study included markers of inflammation and bile duct obstruction. The extent of inflammation was determined from the WBC count and CRP levels of patients. The extent of bile duct obstruction was determined by measuring levels of T-Bil, ALP, AST, ALT and γ-GTP in patients. Abdominal US, MRCP, ERCP and CT diagnostic images were used to evaluate dilatation of the bile ducts. CRP levels were expressed in units of mg/dl (9,16).

Imaging diagnostics. Abdominal US was performed with a SSA-700A ultrasound (Toshiba Medical Systems Corporation, Otawara, Japan). The probes used were a 3.75-MHz curved-array probe (PVT-375BT) or a 3-MHz sector-array probe (PST-308T; both from Toshiba Medical Systems Corporation). MRCP was performed with a 1.5 Tesla scanner using 3.2.2 Achieva software (Philips Medical Systems B.V., Eindhoven, The Netherlands). The MRCP pulse sequences are presented in Table III. CT was performed with a 16-detector-row CT scanner (Siemens AG,
Munich, Germany). CT images were acquired at 130 kV and 200 mA with a rotation time of 0.6 sec and slice pitch of 0.8.

Statistical analysis. Data are presented as the mean ± standard deviation. A χ² test was performed to analyze associations between men and women, the presence of a gallbladder stone and a history of cholecystectomy in the CBDDil(−) and CBDDil(+) groups. One-way analysis of variance followed by a Tukey’s post hoc test was used to compare the age of patients and laboratory test variables between the CBDDil(−) and CBDDil(+) groups. Logistic regression analysis was performed to identify factors affecting dilatation of the CBD. All statistical analyses were performed with JMP 10.0.2 software (SAS Institute, Inc., Cary, NC, USA) and P<0.05 was considered to indicate a statistically significant difference.

Results

Typical cases of CBDDil(−) and CBDDil(+). In one representative patient with CBDDil(+), a CBD stone was identified by CT, abdominal US, MRCP and ERCP (Fig. 1A-D). EPT was performed and the stone was removed (Fig. 1E and F). In one representative patient with CBDDil(−), sludge was identified by abdominal US (Fig. 2A), and MRCP and ERCP revealed that there was no dilatation of the CBD (Fig. 2B and C). Secretions of bile containing sludge from the Ampulla of Vater were also observed (Fig. 2D). CBD stones were identified in two CBDDil(−) patients. Sludge was not detected in any CBDDil(+) patients with abdominal US, CT, or MRCP.

Laboratory test variables. Potential differences between the laboratory test variables and ages of CBDDil(−) and CBDDil(+) patients were evaluated (Table II). The gender ratio did not differ significantly between the CBDDil(−) and CBDDil(+) groups. Patients in the CBDDil(−) group were younger than those in the CBDDil(+) group, although this difference was not significant (66.2±10.3 vs. 70.4±10.0; P=0.0976). CBD diameter was significantly larger in CBDDil(+) patients than in CBDDil(−) patients (P<0.0001). CBDDil(−) patients had significantly higher levels of CRP than CBDDil(+) patients (7.1±8.8 vs. 3.7±5.0; P=0.0392). WBC count and liver enzyme levels did not significantly differ between the CBDDil(−) and CBDDil(+) groups. These data are consistent with previous results indicating that the CBD diameter is generally larger in older patients (14). In addition, the present results suggest that levels of CRP may be associated with CBD dilatation.

To determine whether CBD dilatation was associated with the presence of a gallbladder stone or history of cholecystectomy, a χ² test was performed (Table IV). It was determined that the presence of a gallbladder stone was not correlated with CBD dilatation (P=0.7774). There was also no correlation between history of cholecystectomy and CBD dilatation (P=0.1389). These results suggest that the presence of a gallbladder stone or a history of cholecystectomy has no significant effect on CBD dilatation.

Logistic regression analysis was performed to determine whether patient laboratory test variables or age were associated with the presence of CBD dilatation (Table V). Age and CRP levels were associated with the presence of CBD dilatation (P=0.0193 and P=0.0075, respectively). WBC count and liver enzyme levels were not associated with the presence of CBD dilatation.

Discussion

CBD dilatation is caused by an impairment of bile flow (17,18), which in turn impacts on laboratory test variables. However,
Table IV. Association of CBD dilatation with the presence of a gallbladder stone or history of cholecystectomy.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Common bile duct dilatation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(-)</td>
</tr>
<tr>
<td>GB stone, -/+ (ratio %)</td>
<td>9/14 (39.1/60.9)</td>
</tr>
<tr>
<td>No. of patients with cholecystectomy, -/+ (ratio %)</td>
<td>23/0 (100.0/0.0)</td>
</tr>
</tbody>
</table>

A χ² test was performed to determine whether CBD dilatation was associated with the presence of a gallbladder stone or history of cholecystectomy. (-), bile duct dilatation, gallbladder stone or history of cholecystectomy absent; (+), bile duct dilatation, gallbladder stone or history of cholecystectomy present. CBD, common bile duct; GB, gallbladder.

Table V. Logistic regression analysis of laboratory test variables.

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.9423</td>
<td>0.8786-1.0024</td>
<td>0.0193^</td>
</tr>
<tr>
<td>WBC</td>
<td>0.9998</td>
<td>0.9996-1.0000</td>
<td>0.1648</td>
</tr>
<tr>
<td>CRP</td>
<td>1.1952</td>
<td>1.0589-1.3990</td>
<td>0.0075^</td>
</tr>
<tr>
<td>T-Bil</td>
<td>0.8398</td>
<td>0.5607-1.0889</td>
<td>0.5209</td>
</tr>
<tr>
<td>ALP</td>
<td>1.0003</td>
<td>0.9984-1.0021</td>
<td>0.7491</td>
</tr>
<tr>
<td>AST</td>
<td>1.0021</td>
<td>0.9976-1.0064</td>
<td>0.2201</td>
</tr>
<tr>
<td>ALT</td>
<td>1.0002</td>
<td>0.9945-1.0055</td>
<td>0.8946</td>
</tr>
<tr>
<td>γ-GTP</td>
<td>0.9983</td>
<td>0.9951-1.0008</td>
<td>0.1318</td>
</tr>
</tbody>
</table>

Logistic regression analysis was performed to determine whether patient laboratory test variables or age were associated with the presence of CBD dilatation. ^P<0.05 and ^P<0.01. OR, odds ratio; CI, confidence interval; WBC, white blood cell count; CRP, C-reactive protein; T-Bil, total bilirubin; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase.

some patients with acute cholangitis present with CBD inflammation without dilatation. Hong et al (19) demonstrated that acute cholangitis without CBD dilatation is caused by CBD stones and sludge, with the latter also being implicated in the development of acute cholangitis (20). Interestingly, in one CBDdil(-) patient included in the present study, secretions of bile and sludge from the Ampulla of Vater were observed, indicating that sludge may be present during CBD without CBD dilatation. Collectively, these results suggest that gallbladder sludge may be a cause of acute cholangitis without CBD dilatation. By contrast, the present study observed that levels of T-Bil, ALP, AST, ALT and γ-GTP did not differ significantly between CBDdil(-) and CBDdil(+) patients. This discrepancy with previous results may be due to the relatively small sample size of the current study.

CRP is an acute-phase protein and levels of CRP increase in the blood during inflammation (21). In the present study, CRP levels were significantly higher in CBDdil(-) patients than in CBDdil(+) patients. Previous studies have demonstrated that increased levels of CRP, WBCs and T-Bil are associated with severe acute cholangitis and poor patient prognosis (22,23). In the current study, WBC count and T-Bil levels did not differ significantly between the CBDdil(-) and CBDdil(+) groups, suggesting that the severity of acute cholangitis was similar between the groups. Thus, there may be alternative explanations for the observed elevation in CRP levels in CBDdil(-) patients other than the severity of acute cholangitis. For instance, as CRP is primarily synthesized in the liver in response to interleukin-6 (24), the hepatic production rate of CRP may differ between CBDdil(-) and CBDdil(+) patients. However, the underlying mechanisms responsible for the higher levels of CRP observed in CBDdil(-) patients remain unknown.

Although CBD dilatation aids in the diagnosis of acute cholangitis (9), some patients with acute cholangitis do not exhibit CBD dilatation. For patients without CBD dilatation, imaging diagnostic techniques may allow accurate diagnosis of acute cholangitis. Other indications of CBD inflammation include an increase in magnetic resonance imaging (MRI) signal intensity in the region surrounding the CBD on T2-weighted images (25), or the presence of an abscess near the CBD on CT and MRI images (10,25). As well as imaging diagnostics, laboratory test variables may aid in the diagnosis of acute cholangitis (26). The present study identified an association between CRP levels and the presence of CBD dilatation; thus laboratory test variables may be potential diagnostic factors for the accurate diagnosis of acute cholangitis. Evaluation of the CBD diameter itself may also be key in the diagnosis of acute cholangitis (27).

One limitation of the current study was the small number of patients enrolled. For example, levels of γ-GTP tended to be higher in CBDdil(+) patients than in CBDdil(-) patients, indicating that bile flow may have been disturbed. However, this difference was not significant (P=0.1839), possibly due to the small sample size of the current study (17).

In conclusion, acute cholangitis patients without CBD dilatation were slightly younger and exhibited significantly higher levels of CRP than patients with CBD dilatation. These data indicate that diagnosis of acute cholangitis in patients without CBD dilatation should be based on a combination of clinical symptoms and laboratory data.

References


